Generic, Branded and Biosimilar — Chemotherapy in India

A generic chemotherapy medicine meets the same bioequivalence standard as its branded original — it releases the active molecule into the body in a comparable way, and CDSCO requires this before granting approval. The clinical evidence that established a chemotherapy medicine's effectiveness was generated for the active molecule, not for a specific brand, so that evidence applies to any approved version. What varies between manufacturers is production consistency, not the science behind the medicine.

The price gap can be very large — in some cases a generic costs a small fraction of the branded originator's price for the same active molecule. The gap depends on the specific medicine, how many manufacturers compete in the Indian market, and whether the NPPA has set a ceiling price. Prices change and vary by source, so we do not quote specific figures here. The NPPA website publishes current ceiling prices for scheduled medicines and is the most reliable public reference.

The NPPA sets ceiling prices for medicines on the National List of Essential Medicines (NLEM), which includes a number of chemotherapy agents. A ceiling price is the maximum a manufacturer can charge at retail. Not every cancer medicine is on the NLEM, so not every chemotherapy agent has a regulated ceiling. Medicines not on the list are subject to price monitoring under the Drugs (Prices Control) Order but have more flexibility in pricing.

Chemotherapy medicines are prescription-only and should be sourced through a licensed oncology pharmacy or the pharmacy associated with your treating facility. Buying independently raises questions about storage conditions, cold-chain integrity and authenticity that are difficult to verify outside a controlled supply chain. Some biological medicines require strict temperature management throughout; a break in that chain can affect the medicine before it reaches you.

Tell your oncologist and pharmacist about every medicine you are taking — prescription and over-the-counter, herbal preparations, supplements and traditional medicines. Some of these interact with chemotherapy in ways that are not always obvious from the label. This applies equally to generic versions of prescription medicines: tell the team which version you have and where it came from, especially if it was not dispensed by your treating facility. The team uses this to adjust dosing and watch for interactions.

CDSCO's biosimilar guidelines require a stepwise approach. The manufacturer first shows analytical similarity to the reference biological product, then provides pharmacokinetic data, and then clinical safety and effect data. The amount of clinical evidence required depends on how much can be confirmed from the earlier steps. This is more demanding than the bioequivalence test used for small-molecule generics, which reflects the greater complexity of biological medicines. WHO and ESMO have both published biosimilar guidance that aligns broadly with CDSCO's approach.